22 results about "Bone cancer" patented technology

The present application relates to the field of polymer chemistry and biomedical technology, and particularly relates to a macrocyclic lactone polymer shown in formula (I) which is used for preventing or treating hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Barrett's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer, bladder cancer, colorectal cancer and melanoma, and has the potential to be developed into a new type of antitumor drug.

The ester derivatives of brefeldin A represented by Formula (I) in the inhibition of tumor proliferation. The compounds are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Bart's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer and colorectal cancer, and have the potential to be developed as antitumor agents.

This invention relates to the field of biological testing and discloses a plasma polypeptide marker, COL1A2, associated with tumor bone metastasis and pain, and its applications. To address the difficulties in early diagnosis of bone cancer pain and tumor bone metastasis, this study examined circulating COL1A2 levels in plasma and found that it was significantly upregulated in patients with bone metastasis and pain, and correlated significantly with clinical pain scores and tumor stage. Using enzyme-linked immunosorbent assay (ELISA) technology, a sensitive and specific COL1A2 detection method was established, capable of identifying the occurrence and stage of bone cancer pain and tumor bone metastasis with high predictive efficacy of 0.95 and 0.94, respectively. This assay is low-cost and simple to operate, making it suitable for clinical application. It provides scientific basis and technical support for screening high-risk populations, early diagnosis of bone metastasis, pain staging, and personalized treatment. This invention is of great significance for optimizing diagnostic and treatment strategies for patients with bone cancer pain and improving clinical translation efficiency.

The invention discloses oligopeptide and application thereof in preparation of a medicine for treating and / or relieving pain. The amino acid sequence of the oligopeptide disclosed by the invention comprises a derivative sequence formed by additionally arranging 1-3 amino acids at the N end and / or C end of the amino acid sequence shown as Tyr-Pro-Arg, especially Tyr-Pro-Arg-Arg (YPRR, YR4), and a gastrointestinal tract digestion product Tyr-Pro-Arg (YPR, YR3) of the oligopeptide. The oligopeptide not only can relieve acute pain induced by a mouse thermal drifting model, but also can relieve chronic pain induced by a rat sciatic nerve chronic compression injury model and a tibia bone cancer pain model, and meanwhile, the oligopeptide obviously inhibits CCI-induced spinal astrocyte, microglia and neuron activation; therefore, the compound has important development and application values in the aspects of central sensitization inhibition and analgesia.

The invention relates to the technical field of medicines, in particular to application of anwuligan in preparation of medicines for treating or preventing neuroinflammation related diseases and bone cancer pain. Animal experiments prove that the anwuligan can relieve nerve cell inflammatory response, inhibit tumor cell growth, prevent bone destruction caused by tumors and inhibit mechanical pain sensitivity, heat pain sensitivity and spontaneous pain of bone cancer pain rats. Results show that the anwuligan has potential anti-inflammatory, anti-cancer and analgesic effects and has an application prospect of being developed into a medicine for preventing and treating cancer pain.

This patent application belongs to the field of antibody technology, specifically relating to an anti-NGF monoclonal antibody and its applications. The anti-NGF monoclonal antibody of this patent application can specifically bind to TrkA and p75. The anti-NGF monoclonal antibody of this patent application can be used to treat or prevent NGF-mediated diseases, such as autoimmune arthritis, bone cancer pain, osteoarthritis, and fracture pain.

The present invention relates to a non-invasive magneto-acoustic apparatus for healthy tissue healing and cancer regression comprising at least one pulsed ultrasound unit (LIPUS), at least one permanent magnet, at least one module housing, at least one permanent magnets, at least one control system for controlling pulsed ultrasound unit to energize the unit with desired pulse duration, intensity and active / ON time. The invention is to synchronously use the low intensity pulsed ultrasound (LIPUS) and static magnetic field (SMF) to selectively activate cellular activities specific to cartilage, bone, skin leading to accelerated tissue healing, regeneration. The invention apparatus is to inhibit cancer cellular activities specific to cancers of breast, skin, bone leading to enhanced cancer regression, while leaving the healthy cells unaffected using magneto-acoustic apparatus appropriately. The apparatus exhibit no toxicity to healthy cells and can reduce overall treatment time and costs due to accelerated tissue repair and tumor regression.

The present invention discloses a magnetic resonance-guided focused microwave brain tumor thermal ablation system and a focusing adjustment method. The present invention integrates the three-dimensional data of MRI and CT, selects the microwave frequency suitable for the size and depth of the tumor, and designs a suitable antenna and a cross-polarized antenna phased array. The differential evolution algorithm is used to optimize the antenna output power and phase to achieve precise focusing of microwave energy, increase the tumor temperature to the ablation level, and maintain the safe temperature of healthy tissue. The system effectively suppresses the adverse effects of brain tissue, including the skull, on microwave penetration, and achieves precise ablation of tumors through a small number of antennas combined with an iterative algorithm. Combined with MRI guidance and real-time temperature monitoring, the accuracy and safety of thermal ablation are ensured, non-invasive radical treatment of brain tumors is achieved, and the problem of drugs being unable to penetrate the blood-brain barrier is overcome. In addition, this technology can also be used to treat other diseases such as liver cancer, pancreatic cancer, thyroid cancer, breast cancer, kidney cancer, bone cancer, bladder cancer, and gallbladder cancer.

The invention belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound to preparation of a medicine for treating cancer, the structural formula of the benzothiazepine compound is shown in the formula I, and the cancer is selected from at least one of liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment, the compound shown in the formula I shows clear and different activities of resisting human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventor of the invention finds that the benzothiazepine compound as shown in the formula I has excellent activity on various different types of human tumors for the first time by performing activity screening on a small molecular skeleton, and provides an optional scheme for broad-spectrum anti-cancer drugs.

The present disclosure provides compositions and methods of treating bone cancers, e.g., osteosarcoma in a patient whose age is, for example, at least 2 years old, or at least 12 years old. The method comprises promoting the opening of Cx43 hemichannel in osteocytes by, e.g., using a composition comprising an anti-connexin 43 antibody.

The present disclosure provides compositions and methods for treating osteosarcoma, such as osteosarcoma in a patient who has previously received at least one first-tier osteosarcoma treatment but has failed treatment. The methods comprise promoting the opening of Cx43 hemichannels in bone cells by, for example, using a composition comprising an anticonnexin 43 antibody.

Described herein are crystalline forms of (R)-N-(1-(4-aminobenzyl)-1H-pyrazol-4 -yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido [3′,2′: 4,5]-pyrrolo [1,2-a]pyrazine-2-carboxamide hydrochloride and solvates thereof; pharmaceutical compositions and use thereof in treating cancer such as breast cancer, prostate cancer, lung cancer, brain cancer, skin cancer, bone cancer, ovarian cancer, multiple myeloma and leukemia. Compound (I).

The present invention relates to methods and compositions for the treatment of BAF-related disorders such as melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, and hematologic cancer.

The application belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound in preparation of a cancer treatment drug, wherein the benzothiazepine compound has a structural formula as shown in formula I, and the cancer is at least one selected from liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment of the application, it is found that the compound shown in formula I shows clear and different activities on human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventors of the application find, for the first time, through activity screening on a small molecule skeleton, that the benzothiazepine compound shown in formula I has excellent activity on various different types of human tumors, and the benzothiazepine compound provides an optional scheme for a broad-spectrum anticancer drug.

The invention provides a PLGA (poly (lactic-co-glycolic acid)-PEG (polyethylene glycol)-phosphonate polymer, a bone targeting nanoparticle as well as a preparation method and application of the bone targeting nanoparticle. According to the preparation method of the PLGA-PEG-phosphonate polymer, no catalyst is needed to participate in the reaction, the reaction can be carried out at room temperature, and the preparation method is a green chemical reaction method and is more suitable for large-scale process production requirements; the bone targeting nanoparticle is formed by self-assembly of the PLGA-PEG-phosphonate polymer and PLGA-PEG, the nanoparticle can be specifically combined with hydroxyapatite in bone tissue to realize targeting of the bone tissue, and the nanoparticle can be used as a drug carrier to deliver drugs to the bone tissue, so that the bone targeting nanoparticle has a good application prospect. And bone tissue related diseases such as osteoporosis, bone cancer and osteoarthritis can be treated.

The present disclosure relates to the field of medicinal chemistry, and specifically to brefeldin A derivatives represent by Formula (I) and its use in the inhibition of tumor proliferation activity. The new compounds provided herein are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, lung cancer, Bart's esophageal cancer, gastric cancer, cervical cancer, pancreatic cancer, kidney cancer, endometrial cancer, nasopharyngeal cancer, bone cancer, lymphoma, brain cancer, nerve cancer, oral cancer and colorectal cancer, and have the potential to be developed as novel antitumor agents.

The composition and method for ex vivo expansion of stem cell memory T cells provided by the embodiments of the present disclosure can amplify and culture a cell population with a higher proportion of memory T stem cells, a higher combined proportion of memory T stem cells and central memory T cells, and a higher proportion of natural killer T cells compared to other processes. Additionally, the obtained cell population demonstrates excellent cytotoxic effects against bone cancer and pancreatic cancer cell lines, leading to the production of cell products with enhanced cell therapy efficacy.

The present invention belongs to the technical field of antibodies. Provided are an anti-NGF monoclonal antibody and the use thereof. The anti-NGF monoclonal antibody can specifically bind to TrkA and p75, and can be used for treating or preventing related NGF-mediated diseases, such as autoimmune arthritis, bone-cancer-related pain, osteoarthritis, and fracture-related pain.

The present invention discloses the use of toad venom, its active ingredients, and a combination of its active ingredients in relieving inflammatory pain and bone cancer pain, belonging to the technical field of research on analgesic active ingredients of toad venom. The present invention discovers that toad venom can relieve inflammatory pain and bone cancer pain and clarifies that its main active ingredients are cinobufagin and resefobufogenin. Cinobufagin and resefobufogenin have a good analgesic effect within a certain ratio range. A mass ratio of cinobufagin to resefobufogenin of 4:5 to 5:1 can relieve inflammatory pain, and a mass ratio of cinobufagin to resefobufogenin of 1:10 to 5:1 can relieve bone cancer pain. The present invention also provides the suggestion that the active ingredients cinobufagin and resefobufogenin can become substitutes for the endangered medicinal material toad venom in relieving inflammatory pain and bone cancer pain. In addition, the present invention discovers for the first time that resefobufogenin has an analgesic effect similar to that of morphine and is non-addictive, suggesting that it has the potential to be developed into a new analgesic drug.

The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of SLC26A2, such as certain ovarian, endometrial, brain, bone, and lung cancers, as well as melanoma. A previously identified vanadium-containing compound, bis(maltolato)oxovanadium(IV) (BMOV), specifically provided for killing of SLC26A2 expressing cancer cells in a SLC26A2-dependent manner. The instant disclosure therefore provides for selecting and / or administering BMOV and related vanadium-containing compounds as a therapeutic agent to target a cancer cell and / or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided.

GREM2 compositions and formulations thereof for treating or preventing one or more symptoms of a disease associated with loss of bone mineral density are described. Recombinant GREM2 has been demonstrated to be capable of reducing bone resorption, lowering bone transition markers, and increasing bone strength. Methods of using the GREM2 compositions and formulations are also provided. Preferably, the pharmaceutical formulation containing GREM2 is administered by a parenteral route to prevent or alleviate one or more symptoms of osteoporosis, bone mass reduction, bone fracture and / or bone cancer.